NEW YORK (GenomeWeb News) – Intrexon today announced an agreement to acquire adult stem cell technology firm Medistem for about $26 million.

Based in San Diego, Medistem develops endometrial regenerative cells, which are universal donor adult stem cells that stimulate new blood vessel formation. ERCs can generate different tissues such as heart, brain, pancreas, liver, bone, cartilage, and lung, and Intrexon plans to use its synthetic biology platforms to "engineer a diverse array of cell-based therapeutic candidates using Medistem's multipotent ERCs," it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.